Takeda launches mobile app XPERT EASE to help treatment of genetic disorders

The XPERT EASE application is designed to keep in mind such challenges while managing lysosomal storage disorders, the drug firm said.

Published On 2021-02-27 06:09 GMT   |   Update On 2021-02-27 06:09 GMT

New Delhi: Drug firm Takeda India on Friday said it has launched a mobile application for the exclusive use of healthcare professionals to address the digital ecosystem for the management of patients with genetic diseases.

The application would enable an efficient digital ecosystem for disease updates and dose calculation for improved management of patients with rare lysosomal storage disorders, Takeda India said in a statement.

Screening, diagnosis, and treatment of genetic diseases have often been identified as challenging, including advising the dosage of medicines specific to patients'' individual needs.

The XPERT EASE application is designed to keep in mind such challenges while managing lysosomal storage disorders, the drug firm said.

''At Takeda, we are keen to enable faster diagnosis and access of patients to our medicines and innovative therapies. The XPERT EASE application enables healthcare professionals to raise suspicion index, leading to early diagnosis and better disease management," Takeda India Medical Affairs Head Sandeep Arora said.

Advertisement

Healthcare professionals can access the applications through the Apple App Store and Google Play Store, the company said.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News